IL22 and Alzheimer disease: In AD patients, it causes a decrease in the serum levels of IL-22 and IL-13, cytokines associated with Th22 and Th2 responses, respectively, in the underlying AD immunopathogenesis (Weidinger et al., 2022, 2023b).